Genelux (NASDAQ:GNLX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Genelux (NASDAQ:GNLX) from a sell rating to a hold rating in a report issued on Saturday morning.

Several other brokerages also recently weighed in on GNLX. Benchmark lowered their price objective on Genelux from $25.00 to $23.00 and set a “speculative buy” rating for the company in a research report on Thursday, May 8th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Genelux in a research note on Monday, March 31st. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $17.75.

Genelux Stock Up 5.6%

Shares of NASDAQ:GNLX opened at $3.23 on Friday. The stock has a market cap of $121.88 million, a PE ratio of -3.40 and a beta of -0.49. The company’s fifty day moving average is $2.61 and its 200 day moving average is $3.08. Genelux has a 52 week low of $1.60 and a 52 week high of $5.89.

Genelux (NASDAQ:GNLX) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.03. Sell-side analysts anticipate that Genelux will post -0.88 EPS for the current year.

Hedge Funds Weigh In On Genelux

Several hedge funds have recently made changes to their positions in GNLX. Integrity Alliance LLC. purchased a new stake in Genelux in the first quarter worth $84,000. Jane Street Group LLC bought a new position in Genelux in the 1st quarter worth $190,000. Goldman Sachs Group Inc. purchased a new stake in shares of Genelux in the 1st quarter worth about $239,000. Alyeska Investment Group L.P. purchased a new position in shares of Genelux during the first quarter valued at about $770,000. Finally, Paloma Partners Management Co purchased a new position in shares of Genelux during the first quarter valued at about $135,000. 37.33% of the stock is owned by hedge funds and other institutional investors.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.